Equities
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,209.00
  • Today's Change-1.00 / -0.08%
  • Shares traded1.43m
  • 1 Year change-44.13%
  • Beta0.9715
Data delayed at least 20 minutes, as of Mar 06 2026 13:44 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2025202520242023
ASSETS
Cash And Short Term Investments217213229
Total Receivables, Net1,079973873
Total Inventory1,106986891
Prepaid expenses--7372
Other current assets, total2411835
Total current assets2,6432,2632,100
Property, plant & equipment, net1,4481,3261,141
Goodwill, net393382388
Intangibles, net777774712
Long term investments1036265
Note receivable - long term--1418
Other long term assets------
Total assets5,6715,1334,680
LIABILITIES
Accounts payable--358309
Accrued expenses--266243
Notes payable/short-term debt--2146
Current portion long-term debt/capital leases114632115
Other current liabilities, total624701626
Total current liabilities1,4531,9781,339
Total long term debt1,4906531,030
Total debt1,6041,3061,191
Deferred income tax161825
Minority interest131111
Other liabilities, total10616377
Total liabilities3,0782,8232,482
SHAREHOLDERS EQUITY
Common stock404040
Additional paid-in capital282282282
Retained earnings (accumulated deficit)2,2712,3992,195
Treasury stock - common--(37)--
Unrealized gain (loss)------
Other equity, total--(374)(319)
Total equity2,5932,3102,198
Total liabilities & shareholders' equity5,6715,1334,680
Total common shares outstanding222222221
Treasury shares - common primary issue131313
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.